BELITE BIO, INC (BLTE) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 2 funds adding, and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $32.3M sold). Latest close $156.23 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 12, 2026 · Congress to Nov 16, 2026.
Paradigm Biocapital Advisors · RTW Investments · Deerfield Management — 5 tracked funds hold BLTE. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 50 sales ($32.3M). Insider trading
SAVARA INC (SVRA) · ERASCA INC (ERAS) · TARSUS PHARMACEUTICALS INC (TARS) · Abivax S.A. (ABVX) · ALNYLAM PHARMACEUTICALS, INC. (ALNY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Paradigm Biocapital Advisors | 3.55% | 1,232,877 | ADDED (+10.6%) Q3 filed Nov 16 |
| RTW Investments | 0.94% | 715,332 | HELD Q3 filed Nov 16 |
| Deerfield Management | 0.57% | 357,199 | ADDED (+17.5%) Q3 filed Nov 16 |
| Maverick Capital | 0.54% | 396,311 | NEW Q3 filed Nov 16 |
| OrbiMed Advisors | 0.04% | 13,300 | NEW Q3 filed Nov 16 |
| Perceptive Advisors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +10.8% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 81 of 8,857 filers |
| Long-only filers among them | 81 |
| Change vs 2026 Q1 | +6 net · 80 entered · 74 exited |
| Shares reported, all filers | 9,473,460 |
| Reported value, all filers | $1.4B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Net income · FY2025 | $-77.6M |
| Total assets · FY2025 | $780.6M |
| Shares outstanding | 39,339,960 |
| Market cap (at latest close) | $6.1B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Oct 15, 2026 | 1,267,440 |
| Share of shares outstanding | 3.22% |
| Days to cover | 7.11 |
Shares short at recent settlements — Jul 31, 2026: 1.1M · Aug 14, 2026: 1.1M · Aug 31, 2026: 1.0M · Sep 15, 2026: 1.1M · Sep 30, 2026: 1.1M · Oct 15, 2026: 1.3M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 27 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 50 sales by 3 insiders ($32.3M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 500 | $162.04 | $81.0K | SEC filing |
| Nov 12, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 500 | $164.68 | $82.3K | SEC filing |
| Nov 12, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 500 | $166.82 | $83.4K | SEC filing |
| Nov 12, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 500 | $170.41 | $85.2K | SEC filing |
| Oct 1, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 200 | $163.62 | $32.7K | SEC filing |
| Oct 1, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 24 | $164.64 | $4.0K | SEC filing |
| Oct 1, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 120 | $165.49 | $19.9K | SEC filing |
| Oct 1, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 50 | $166.44 | $8.3K | SEC filing |
| Oct 1, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 78 | $167.59 | $13.1K | SEC filing |
| Oct 1, 2026 | Scholl Hendrik Peter | Chief Medical Officer | Sell | 12 | $168.21 | $2.0K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Hendrik Peter Scholl | Officer | 4,000 | $679.3K | Oct 1, 2026 | SEC filing |
| Aug 12, 2026 | Yu-Hsin Lin | CEO, Chairman | 126,800 | $22.5M | Aug 12, 2026 | SEC filing |
| Aug 12, 2026 | Hao-Yuan Chuang | Officer, Director | 93,800 | $16.7M | Aug 12, 2026 | SEC filing |
| Jun 18, 2026 | Dr. Hendrick P. Scholl | Affiliate | 10,000 | $1.5M | Jun 18, 2026 | SEC filing |
| Jun 16, 2026 | Dr. Hendrick P. Scholl | Affiliate | 10,000 | $1.4M | Jun 16, 2026 | SEC filing |
| Apr 15, 2026 | Nathan L. Mata | Officer | 16,666 | $2.9M | Apr 15, 2026 | SEC filing |
| Apr 9, 2026 | Wan Shan Chen | affiliate | 10,196 | $2.2M | Apr 9, 2026 | SEC filing |
| Apr 9, 2026 | Yu-Hsin Lin | CEO, Chairman | 136,000 | $24.3M | Apr 9, 2026 | SEC filing |
| Apr 9, 2026 | Hao-Yuan Chuang | Officer, Director | 100,000 | $17.9M | Apr 9, 2026 | SEC filing |
| Oct 17, 2025 | Wan Shan Chen | Affiliate | 9,550 | $1.2M | Oct 17, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | Yu-Hsin Lin | SC 13G/A | 1,253,935 | 3.1% | Mar 31, 2026 | SEC filing |
| Feb 17, 2026 | Darwin Global Management, Ltd. | SC 13G/A | 3,027,704 | 8.1% | Dec 31, 2025 | SEC filing |
| Dec 10, 2025 | Darwin Global Management, Ltd. | SC 13G | 2,617,094 | 7.0% | Dec 3, 2025 | SEC filing |
| Jan 21, 2025 | Yu-Hsin Lin | SC 13G | 2,287,070 | 7.1% | Dec 31, 2024 | SEC filing |
| Jan 21, 2025 | Lin Bioscience International Ltd. | SC 13G | 17,095,263 | 53.7% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Red Flags
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Excess Accruals (Sloan) — Accruals ratio: 33.9% · Net income: $-77.6M · Operating cash flow: $-37.0M · Investing cash flow: $-305.1M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold BLTE — ranked by lift, the co-holding pattern described in Methodology: SAVARA INC (SVRA) · ERASCA INC (ERAS) · TARSUS PHARMACEUTICALS INC (TARS) · Abivax S.A. (ABVX) · ALNYLAM PHARMACEUTICALS, INC. (ALNY) · COGENT BIOSCIENCES INC (COGT) · DISC MEDICINE INC (IRON) · SPYRE THERAPEUTICS INC (SYRE).
No Form 8-K filings for this ticker in the index (Jan 2023 – present).
SAVARA INC (SVRA) · Track Record: how the signals scored · Practice timing on BLTE
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.